ArticleJournal of health economics2022
Vaccination strategies and transmission of COVID-19: Evidence across advanced countries.
Article in Journal of health economics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Motivational effectiveness of prosocial public health messaging to reduce respiratory infection risk: a systematic review and meta-analysis.Communications medicine · 2025Article
- Article
- Completion of Multidose COVID-19 Vaccination Among Adolescents and Adults in Urban Informal Settlements in Nairobi, Kenya.The American journal of tropical medicine and hygiene · 2025Article
- Burden of acute and long-term COVID-19: a nationwide study in Bahrain.Frontiers in public health · 2025Observational
- Impact of the first year of COVID-19 vaccination strategy in Brazil: an ecological study.BMJ open · 2024Article
- Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan.Clinical and experimental vaccine research · 2023Article
- Risk of Testing Positive for COVID-19 among Healthcare and Healthcare-Related Workers.Vaccines · 2023Article
- Article
- Article
- Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.The Lancet. Public health · 2023Article
- Vaccine selection for COVID-19 by AHP and novel VIKOR hybrid approach with interval type-2 fuzzy sets.Engineering applications of artificial intelligence · 2023Article
- Understanding Covid-19 Mobility Through Human Capital: A Unified Causal Framework.Computational economics · 2023Article
- COVID-19 vaccine strategies must focus on severe disease and global equity.Lancet (London, England) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given limited supply of approved vaccines and constrained medical resources, design of a vaccination strategy to control a pandemic is an economic problem. We use time-series and panel methods with real-world country-level data to estimate effects on COVID-19 cases and deaths of two key elements of mass vaccination - time between doses and vaccine type. We find that new infections and deaths are both significantly negatively associated with the fraction of the population vaccinated with at least one dose. Conditional on first-dose coverage, an increased fraction with two doses appears to offer no further reductions in new cases and deaths. For vaccines from China, however, we find significant effects on both health outcomes only after two doses. Our results support a policy of extending the interval between first and second doses of vaccines developed in Europe and the US. As vaccination progresses, population mobility increases, which partially offsets the direct effects of vaccination. This suggests that non-pharmaceutical interventions remain important to contain transmission as vaccination is rolled out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.